INtRON Biotechnology Ownership

048530 Stock  KRW 3,840  30.00  0.78%   
iNtRON Biotechnology has a total of 29.88 Million outstanding shares. INtRON Biotechnology retains 15.72 (percent) of its outstanding shares held by insiders and 8.1 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as INtRON Biotechnology in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of INtRON Biotechnology, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in iNtRON Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

INtRON Stock Ownership Analysis

About 16.0% of the company shares are owned by insiders or employees . The company has Price/Earnings (P/E) ratio of 313.17. iNtRON Biotechnology had not issued any dividends in recent years. The entity had 2:1 split on the 10th of January 2019. iNtRON Biotechnology, Inc., a biotechnology company, develops bacterial bio-drugs for the treatment of infectious diseases. In addition, the company develops drugs targeting functional moieties, including axakacin, pterostilbene, methylated flavonoid, etc. for use in silver and brain industries. iNtRON Biotechnology, Inc. was founded in 1999 and is headquartered in Seongnam, South Korea. iNtRON Bio is traded on Korean Securities Dealers Automated Quotations in South Korea. For more info on iNtRON Biotechnology please contact the company at 82 3 1739 5678 or go to https://www.intron.co.kr.

INtRON Biotechnology Outstanding Bonds

INtRON Biotechnology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. iNtRON Biotechnology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most INtRON bonds can be classified according to their maturity, which is the date when iNtRON Biotechnology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Pair Trading with INtRON Biotechnology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if INtRON Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in INtRON Biotechnology will appreciate offsetting losses from the drop in the long position's value.

Moving together with INtRON Stock

  0.78105560 KB Financial GroupPairCorr
  0.77055550 Shinhan FinancialPairCorr

Moving against INtRON Stock

  0.83316140 Woori Financial GroupPairCorr
  0.54036460 Korea GasPairCorr
The ability to find closely correlated positions to INtRON Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace INtRON Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back INtRON Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling iNtRON Biotechnology to buy it.
The correlation of INtRON Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as INtRON Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if iNtRON Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for INtRON Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in INtRON Stock

INtRON Biotechnology financial ratios help investors to determine whether INtRON Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in INtRON with respect to the benefits of owning INtRON Biotechnology security.